Regorafenib as second-line treatment for patients with HCC who progressed on sorafenib: Japanese subgroup analysis of phase 3 RESORCE trial

Published on Jan 1, 2017
Yokosuka Osamu1
Estimated H-index: 1
Meinhardt Gerold1
Estimated H-index: 1
Jordi Bruix1
Estimated H-index: 1
  • References (0)
  • Citations (1)
Cited By1
#1Changhoon Yoo (UOU: University of Ulsan)H-Index: 16
#2Joong Won ParkH-Index: 24
Last. Ho Yeong Lim (SKKU: Sungkyunkwan University)H-Index: 25
view all 9 authors...
Background The pivotal RESORCE trial showed that regorafenib was effective as second-line therapy for patients with advanced HCC who progressed on first-line sorafenib. Real-world data are needed to assess clinical outcomes and adverse events in the setting of daily practice. Methods Between April 2017 and August 2017, the Named Patient Program (NPP) was activated to provide controlled, pre-approval access of regorafenib in Korea. This analysis is a multicenter retrospective study of patients wh...
2 CitationsSource